Estimating average inpatient and outpatient costs and childhood pneumonia and diarrhoea treatment costs in an urban health centre in Zambia.

PubWeight™: 1.06‹?› | Rank: Top 10%

🔗 View Article (PMC 2770026)

Published in Cost Eff Resour Alloc on October 21, 2009

Authors

Lumbwe Chola1, Bjarne Robberstad

Author Affiliations

1: Central Statistical Office, Box 31908, Lusaka, Zambia. lumbwe.chola@cih.uib.no

Articles cited by this

Where and why are 10 million children dying every year? Lancet (2003) 28.59

WHO estimates of the causes of death in children. Lancet (2005) 18.33

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet (2005) 7.99

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet (2007) 4.45

Allowing for differential timing in cost analyses: discounting and annualization. Health Policy Plan (2002) 1.83

Using burden of disease information for health planning in developing countries: the experience from Uganda. Soc Sci Med (2003) 1.70

The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis. Cost Eff Resour Alloc (2009) 1.53

Costs and revenue of health care in a rural Zimbabwean district. Health Policy Plan (2005) 1.30

The costs of hospital services: a case study of Evangelical Lutheran Church hospitals in Tanzania. Health Policy Plan (1998) 1.13

Economic analysis of childhood pneumonia in Northern Pakistan. Health Policy Plan (2008) 0.98

Evaluating the costs of pneumococcal disease in selected Latin American countries. Rev Panam Salud Publica (2007) 0.90

The burden of pneumonia in children in Latin America. Paediatr Respir Rev (2005) 0.89

Functional characterization of a putative aquaporin from Encephalitozoon cuniculi, a microsporidia pathogenic to humans. Int J Parasitol (2005) 0.87

Articles by these authors

Age and severity. Tidsskr Nor Laegeforen (2015) 1.98

Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy. AIDS Res Ther (2010) 1.43

Cost and cost-effectiveness of community based and health facility based directly observed treatment of tuberculosis in Dar es Salaam, Tanzania. Cost Eff Resour Alloc (2005) 1.32

[Re: Markov modeling]. Tidsskr Nor Laegeforen (2015) 1.06

Explaining household socio-economic related child health inequalities using multiple methods in three diverse settings in South Africa. Int J Equity Health (2011) 1.01

The relationship between prevention of mother to child transmission of HIV and stakeholder decision making in Uganda: implications for health policy. Health Policy (2003) 0.94

[The challenges of subject criticism]. Tidsskr Nor Laegeforen (2013) 0.92

Maternal and perinatal mortality by place of delivery in sub-Saharan Africa: a meta-analysis of population-based cohort studies. BMC Public Health (2014) 0.92

Cost of individual peer counselling for the promotion of exclusive breastfeeding in Uganda. Cost Eff Resour Alloc (2011) 0.89

Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malar J (2014) 0.89

Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review. BMC Med Inform Decis Mak (2012) 0.85

Infant feeding survival and Markov transition probabilities among children under age 6 months in Uganda. Am J Epidemiol (2013) 0.78

Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia. Cost Eff Resour Alloc (2009) 0.77

[In Process Citation]. Tidsskr Nor Laegeforen (2015) 0.75

Response to "reply to: economic evaluation of second generation pneumococcal conjugate vaccines in Norway". Vaccine (2012) 0.75

[Does budget consequences control Norwegian reimbursement priorities?]. Tidsskr Nor Laegeforen (2013) 0.75